Review top news and interview highlights from the week ending July 15, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
There were not enough data at 6 months to predict expanded disability status scale (EDSS) improvements after treatment.
Patient recruitment for the clinical trial is currently underway at epilepsy centers throughout the US.
Verve Therapeutics is currently conducting a clinical trial in New Zealand and expects to be able to open trials in the UK and US later in 2022.
SCG101 will be evaluated in trials across China, Singapore, and the US.
Legend Biotech seeks to prioritize other product candidates in its pipeline.